Pay attention to the dates! Make a note !
$Atara Biotherapeutics(ATRA.US$ Tab-cel U.S. BLA on Track for Submission in Q2 2024 Following Positive Pre-BLA Meeting
Allogeneic CAR T Pipeline Expands Into Autoimmune Disease With Plans To Initiate a ATA3219 Lupus Nephritis Study in H2 2024, and Initial Clinical Data Expected H1 2025
ATA3219 NHL Study Enrolling With Initial Clinical Data Expected in Q4 2024
Cash Runway Into 2027 Enables Key Pipeline Readouts
Allogeneic CAR T Pipeline Expands Into Autoimmune Disease With Plans To Initiate a ATA3219 Lupus Nephritis Study in H2 2024, and Initial Clinical Data Expected H1 2025
ATA3219 NHL Study Enrolling With Initial Clinical Data Expected in Q4 2024
Cash Runway Into 2027 Enables Key Pipeline Readouts
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
TrytosaveabitOP SpyderCall: GM! Hope you’re having a great weekend! Yes that’s pretty encouraging, I believe! I thank you for sharing!